BioCentury
ARTICLE | Clinical News

PLX3397: Additional Phase I data

June 2, 2014 7:00 AM UTC

Data from 14 evaluable patients with advanced pigmented villonodular synovitis (PVNS) in an extension cohort of an open-label, U.S. Phase I trial in about 150 patients with advanced solid tumors showed that once-daily 1,000 mg oral PLX3397 led to 11 partial responses and 3 cases of stable disease. Mean tumor size reduction was 61% and clinical improvements were observed in pain, stiffness and overall function. The extension cohort has enrolled 23 patients with PVNS. PVNS is a proliferative neoplastic tumor that affects the synovium and tendon sheaths in young and middle-aged adults. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Daiichi previously reported data from 26 patients with advanced solid tumors in the trial showing that once-daily 100-900 mg doses of oral PLX3397 were well tolerated (see BioCentury, June 6, 2011). ...